International Journal of Artificial Intelligence and Cybersecurity

https://ijaics.org/

RESEARCH ARTICLE

Advancements in AI-Driven Smart Nanocarriers for Controlled and Sustained Drug Release in Cancer Therapy

Syed Nigam[1], Darvin Wilson[2]

[1] University of Arizona

[2] Ball State University

ARTICLE INFO

Received: Jan 01, 2025
Accepted: Jan 10, 2025

Keywords

Artificial Intelligence, Nanotechnology, Smart Nanocarriers, Cancer Therapy, Targeted Drug Delivery, Controlled Drug Release, Personalized Treatment, Drug Release Kinetics, Nanoparticles

***Corresponding Author:**
Nigam154@gmail.com

ABSTRACT

Advanced cancer therapy has benefited significantly from the union of AI technology with nanotechnology by making possible intelligent nanocarriers that exist as effective platforms for sustained drug delivery. The artificial intelligence systems work by optimizing nanocarrier designs to provide selective drug delivery toward cancer sites without harming healthy tissue. AI algorithms optimize cancer therapy through personalization by evaluating unique patient data including genetic profiles alongside tumour elements in order to generate nanocarriers designed for specific requirements. Through AI control systems researchers can track drug release along with maintaining precise drug delivery concentrations during time-sensitive processes. The precise control of drug delivery through these systems increases therapeutic effects while reducing side effects thus resulting in superior patient results. The development of AI-driven smart nanocarriers presents a dramatic shift for cancer treatment while facing current obstacles of scale-up together with regulatory clearance but allows groundbreaking advancements in patient-specific treatments with increased effectiveness and lower toxicity levels during the future.

I. INTRODUCTION

Cancer stands as one of the most complex diseases for treatment because each year millions of people succumb globally to the condition. Advancements in cancer therapy exist but conventional treatment options like chemotherapy and radiation continue to face substantial obstacles when delivering both therapeutic precision and patient tolerance [1]. Traditional cancer treatments exhibit limited drug delivery effectiveness since their broad specify causes harmful effects to healthy tissues thus lengthening recovery periods as well as increasing toxicity. Scientists now heavily research oncology drug delivery systems because they need targeted approaches that maximize efficiency and tailor medications to individual patients [2].

Smart nanocarriers represent one of the most promising innovative drug delivery approaches since these systems target cancer cells specifically and minimize damage to nearby healthy tissue. Medical nanotechnology allows scientists to modify materials at nanoscale dimensions between 1 to 100 nanometres and they have revolutionized medical fields particularly cancer therapy. Scientists have used nanoparticles including liposomes dendrimers and polymeric micelles to create drug delivery platforms which improve chemotherapy drug stability and bioavailability while enhancing their solubility [3]. Research demonstrates that the combination of Artificial Intelligence (AI) with nanotechnology conducts a transformative impact on cancer treatment through advanced drug delivery system technology. The application of Artificial Intelligence optimizes nanoparticle designs yet simultaneously enables predictions about drug release patterns and customized treatments grounded in patient-specific profiles to advance oncology treatments.

AI-driven smart nanocarriers demonstrate a capability to control therapeutic agent release through precise delivery over time [4]. The current drug delivery methods depend on delivering medicines in static doses during scheduled times but this practice leads to suboptimal drug levels and unacceptable adverse effects. Smart nanocarriers function using integrated stimuli responses that detect tumour acidity to deliver drugs exactly where they need to be. Machine learning algorithms enhance nano-platform mechanisms which adjust medication delivery rates to maintain precise dosage control throughout prolonged timeframes thus obtaining maximum effectiveness and limiting negative consequences [5]. Smart nanocarriers revolutionize drug delivery because they release medication specifically at targeted locations which brings immense value to chemotherapy patients who suffer equally intense side effects from their treatment as from their illness. Patients gain an improved level of personalized cancer treatment through artificial intelligence integration [6]. Through data analysis of genetic and molecular and environmental factors AI systems generate tailored therapies designed specifically for each patient. Cancer cases exhibit distinct patterns because every patient has different genetic mutation profiles and unique tumour environments which react differently to therapeutic options.

The integration of extensive biological data enables AI to develop nanocarriers which detect individual cancer biomarkers and thus lead to enhanced therapeutic outcomes. With predictive abilities AI models evaluate how specific drug delivery systems will affect a patient's tumour therefore enabling better clinical decisions through modified treatment strategies [7]. The move toward customized medical care through personalized treatments enables better outcome results while decreasing potential adverse effects because medications precisely match a patient's unique cancer properties. The combination of artificial intelligence with smart nanocarriers leads to superior drug delivery tracking alongside adaptable release mechanisms. Real-time analytics transmitted from AI-driven wearable sensors enable direct observation of nanocarriers working inside the body through monitoring drug release behaviour and tissue absorption and therapeutic effects [8]. Real-time feedback systems let these medical devices automatically modify drug release parameters to ensure the treatment stays within its optimal wellness zone.

Within drugs characterized by low therapeutic margins it becomes essential to achieve perfect dose ratios to avoid suboptimal or excessive treatment levels. By monitoring nanoparticle dispersion patterns throughout the body AI technology finds the most beneficial strategy for drug distribution across tumour areas. The continuous feedback system enables treatment optimization through effective delivery and adaptation which sustains maximum patient advantage while avoiding toxic complications [9]. The huge potential benefits of AI-controlled smart nanocarriers for cancer therapy remain restricted by various technical obstacles which limit their mass deployment. Manufacturing advanced drug delivery systems at large volume stands as a major challenge since their full-scale production remains expensive and technically complex [10].

These novel technologies encounter prolonged regulatory delays because regulatory organizations need time to verify safety and effectiveness standards for clinical use. The delivery of advanced therapies depends on resolving ethical questions about privacy protections along with the use of artificial intelligence in decision-making algorithms and potential algorithmic bias problems to build trust with patients while providing fair treatment access. The promising future for oncology appears bright because of the emerging collaboration between AI and nanotechnology in cancer therapies [11]. Through AI-powered smart nanocarriers scientists develop methods to optimize cancer drug delivery precision so dosage can be combined with patient-specific treatment and reduced toxicities leading to improved alternatives over traditional cancer medicine. Personalized data-driven oncology delivery will strengthen in the future because technological advancements enable genetic-based tumour treatment methods and patient-specific care plans. The convergence of Artificial intelligence with nanotechnology systems creates therapeutic possibilities which promise to completely transform cancer treatment parameters while providing improved results coupled with superior patient outcomes and extended survival durations.

I. Research Findings

A. AI-DRIVEN SMART NANOCARRIERS IN CANCER TREATMENT

Smarter cancer therapies appear promising through the use of AI-powered smart nanocarriers for precise drug delivery systems. Smart nanocarriers unite nanotechnology bases with artificial intelligence components to address traditional drug delivery constraints that cause widespread drug distribution as well as severe side effects. Scientists design smart nanocarriers to target cancer cells alone because these carriers deliver therapeutic agents to tumours without causing damage to adjacent healthy tissues. This section demonstrates how artificial intelligence augments nanocarrier performance through system enhancements that include design methods and targeting features along with treatment agent control systems [12].

i. Nanocarrier Design and Optimization Through AI

Multiple design elements shape nanocarrier development because manufacturers must determine dimensions as well as surface properties and types of construction materials. These structural features determine the nanocarrier system's capacity to move through biological systems while reaching tumour cells and deploying therapeutic compounds. Nanocarrier development using traditional methods requires considerable resources and generates significant time expenditures through basic experimentation. AI-driven design tools enhance nanocarrier development through database analysis which produces predictions for optimal structural properties dedicated to maximizing drug delivery effectiveness [13].

ii. Machine learning algorithms

Machine learning algorithms review nanotechnology experimental data about nanoparticle dimensions and structural features and surface chemical modifications to generate insights about effective cancer cell targeting properties. Artificial intelligence models demonstrate the ability to forecast biological environment interactions of nanoparticles through examination of blood flow and tumour microenvironment and immune system reactions [14]. The predictive properties of this technology enable researchers to create nanocarrier designs which successfully avoid natural defines barriers and transport drugs straight to cancer cells. The targeted delivery enabled by AI-based nanocarrier optimization results in drug delivery systems that function efficiently with reduced side effects.

iii. Targeting Cancer Cells with AI-Powered Nanocarriers

The main strength of intelligent nanocarriers controlled by artificial intelligence lies in their specific targeting of cancer cells. The surfaces of tumours show distinctive biomarkers through surface receptor overexpression that serves to distinguish cancer cells from normal cells. AI algorithms perform analysis of genomic studies alongside patient records and tumour imaging data in order to detect specific biomarkers. Nanoparticles receive specific receptors due to information processing which enables the employment of receptor-specific ligands and antibodies to define drug delivery exclusively to cancer tumours. Artificial intelligence tools enable researchers to detect universal biomarkers existent across multiple cancer types which enables widespread therapeutic targeting programs. When assessing genetic data and molecular profiles from individual patients AI generates designed nanocarrier solutions customized specifically for each person's tumour conditions. The individualized treatment increases the efficiency rate and reduces unwanted side effects. AI advances nanocarrier targeting through intelligent design methods to deliver drugs precisely to their therapeutic sites which improves cure rates while decreasing drug distribution in normal tissues.

B. AI-OPTIMIZED DRUG RELEASE: CONTROLLED AND SUSTAINED DELIVERY

The fundamental issue in cancer therapy revolves around maintaining drug effectiveness throughout treatment duration while minimizing toxic consequences. The administration of traditional chemotherapy treatments through high-dose intermittent delivery methods creates substantial adverse effects owing to uncontrolled drug release. The innovative design of AI-optimized smart nanocarriers enables researchers to execute precise and continuous drug delivery schedules. This segment examines how Artificial Intelligence controls drug release kinetics and evaluates the advantages of prolonged drug delivery platforms [15].

i. Stimuli-Responsive Drug Release Mechanisms

Smart nanocarriers integrate drug release features that allow them to activate their payload only in response to precise stimuli found within tumour microenvironments including pH alterations or temperature changes or enzyme and protein events. The nanocarriers contain smart stimuli-responsive mechanisms which activate drug delivery when they enter the target location thus reducing adverse drug effects in other body parts. AI-based systems achieve optimal release functionality by incorporating tumour-specific analyses to create nanocarriers that function according to specific environmental cues [16]. Tumour acidity stands as a phenomenon that causes cancer cells to maintain an acidic environment when compared to standard cells. Artificial intelligence systems enable scientists to engineer pH-aware nanocarriers which release their contents exclusively when they reach the cancerous tissue environment. AI simulation enables researchers to manage and evaluate nanocarrier conduct throughout tumour environments thus promoting drug release in targeted areas. The cellular release of cytotoxic drugs becomes more accurate through this method which simultaneously improves therapeutic effects while decreasing negative side effects.

ii. AI-Driven Real-Time Monitoring of Drug Release

Data from smart nanocarrier drug release monitoring reaches healthcare providers through real-time monitoring devices in order to adjust treatment protocols successfully [17]. Smart nanocarriers include embedded tracking sensors that monitor drug release which sends information to AI systems helping these systems make adjustments to deliver drugs at their best therapeutic endpoint. Implementing this capability becomes especially vital for treatments utilizing drugs with restricted therapeutic boundaries because precise medication delivery directly influences patient safety outcomes. Through real-time monitoring systems healthcare professionals can make drug dosage adjustments specifically based on patient reaction patterns. The tumour’s evolving size and medical response to therapy is assessed by AI systems through tracked sensor feedback which permits precise treatment drug dosage adjustments. The personalized delivery system optimizes drug effects and reduces drug unnecessary exposure to provide improved treatment safety along with better treatment results for cancer patients [6].

iii. PERSONALIZED CANCER TREATMENT WITH AI AND NANOTECHNOLOGY

AI and nanotechnology bring tremendous promise in customized cancer therapies which stands as a key forward-moving feature of this advancing field. Each patient's cancer displays high heterogeneity which results in diverse tumour genetic profiles along with their growth patterns and treatment responses. Doctors must customize their cancer treatments in order to achieve better outcomes for patients. Smart nanocarriers enabled by AI allow designers to develop responsive treatment systems which adapt to individual tumour conditions therefore maximizing treatment outcomes with minimal unwanted effects [18].

C. AI in Genomic and Molecular Profiling for Personalized Nanocarrier Design

Artificial Intelligence uses molecular and genomic patient data to detect personalized cancer mutations along with unique gene expressions and protein profiles. AI leads to the development of custom nanocarriers because it processes information about biomarkers particular to each individual's tumour tissue [12]. Personalized nanocarriers transformation through this approach enables researchers to create delivery vehicles which guide medications to cancer cells according to their individual characteristics. The predictive capabilities of AI enable healthcare providers to understand tumour drug responses therefore enabling optimal choice selection of therapeutic approaches. The realistic analytical approach based on data use decreases the probability of drug resistance while optimizing overall treatment performance. The combination of genomics and proteomics and imaging data through AI powers precise targeted cancer treatments which produce superior clinical results.

i. Enhancing Nanocarrier Stability and Bioavailability Through AI

Nanocarriers demonstrate outstanding capacity to enhance cancer drug delivery by making therapeutic agents more soluble while simultaneously increasing their stability and prescription accuracy. Success with these delivery systems depends highly on body-stable nanocarriers and on accessible encapsulated drugs. Drugs delivered through nanocarriers achieve optimal performance thanks to AI optimization which guarantees effectiveness and efficiency across the entire medication transport process [19].

a. Improving Nanocarrier Stability in Biological Environments

Controlling nanocarriers stability represents a core challenge during drug delivery processes between circulation through the bloodstream and reaching their designated target location. Life environments expose nanocarriers to multiple elements like enzymes while they withstand temperature changes and ionic situations but these elements speed degradation while causing unstable aggregation thus decreasing their delivery success [20]. The implementation of machine learning prediction methods through Artificial Intelligence applications leads to optimized nanocarrier designs for biological environments. AI models provide simulations and analyses of nanocarrier-biological entity interactions to modify surface characteristics including surface charge and hydrophilicity thus enhancing product stability. Through these predictive model scientists determine how various nanoparticle materials maintain stability while preventing drug release too soon. Constructing stronger nanocarriers for therapy through AI presents the ability to make enhancements in both material construction and structure which increases system durability under biological conditions for accurate drug reach at tumour sites without premature drug loss [21].

b. Increasing Drug Bioavailability Through AI Optimization:

Highly water-insoluble drugs face major delivery issues because of their limited biological availability. Anticancer drugs tend to have low solubility rates that produce limited drug availability and reduced therapeutic efficiency when using standard drug delivery approaches. Through AI optimization nanocarrier formulations achieve increased drug solubility alongside elevated bioavailability rates [22]. The analysis of extensive combinations of drug specifics alongside nanocarrier mechanics enables AI systems to create recommendations for optimal partner materials and encapsulation approaches leading to better drug absorption. Artificial intelligence develops predictive models that describe how changes to nanocarrier shapes along with sizes and surface characteristics influence drug release behaviour in different biological environments. Drugs can be optimized through this process to release at controlled sustained rates which results in both better drug efficacy and longer-duration therapeutic benefits. The use of AI optimization enables nanocarriers to attain optimal configuration which enhances drug bioavailability of poorly soluble treatments making them more beneficial in cancer therapy [23].

ii. Clinical Applications and Case Studies of AI-Driven Nanocarriers in Cancer Treatment

The application of AI-driven nanocarriers in cancer treatment forms a promising frontier of oncology that enhances both therapy effectiveness and delivery system precision. Modern cancer treatment combines nanotechnology targetability with artificial intelligence prediction capabilities to create personalized therapy solutions for cancer patients. A review of realistic solutions integrated with AI-based nanocarriers displays their clinical trial implications through case studies and investigates the pathways from laboratory work to medical utilization of such technology for cancer therapy across multiple cancer types [24].

iii. Case Studies of AI Nanocarriers in Clinical Trials

Current clinical trial data proves that AI-enhanced nanocarriers show both practical usage alongside successful results for various cancer types. These case study examples show that integrating AI technology improves drug delivery accuracy by resolving problems with target selection and efficiency and reducing harmful side effects [7]. Lung cancer patients who receive chemotherapy with AI-enhanced liposomes show improved targeted drug delivery in clinical practice. AI technology enables scientists to transform liposomal nanoparticles by optimizing their dimensions while also transforming their surface electrostatic qualities and their functional properties to ensure efficient body navigation and targeted tumour accumulation. AI-powered liposomes demonstrated a clinical trial success in delivering doxorubicin chemotherapy drugs precisely to lung tumours while reducing both side effects and healthy tissue exposure during this study. AI-based real-time calculations of nanoparticle dynamics enabled healthcare workers to modify both dosage amounts and drug release patterns which produced better therapeutic effects alongside enhanced patient response [18].

iv. Translating AI Nanocarrier Research into Clinical Practice

AI-driven nanocarriers demonstrate promising results in clinical trials but implementing these innovations across clinical settings requires resolution of multiple practical difficulties. The transition from laboratory research to clinical use requires handling multiple technical, regulatory and logistical obstacles that create delays before these modern treatments reach medical facilities. Scale-up presents one of the greatest barriers in this domain. The large-scale production of high-quality AI-enhanced nanocarriers is a major technical hurdle which designers must overcome. The production of nanoparticle systems and their surface modifications demands complex manufacturing protocols combined with precise regulation of fundamental parameters like particle dimensions and charge values along with drug packaging efficiencies. The manufacturing methods for advanced therapies must fulfil requirements of scalability and reproducibility and reduced manufacturing costs to enable patient access [25]. For wide applicability across patient populations AI models require extensive training and validation of large datasets with diverse components. The process of obtaining regulatory authorization stands as a vital obstacle. Clinical trials show the success of AI-powered nanocarriers however regulatory bodies particularly the FDA and EMA require standards for their approval process. AI-based nanocarriers require satisfying complete safety profile requirements together with meeting demanding standards for efficiency and biocompatibility performance [9].

D. Nanocarriers for Targeting Specific Cancer Subtypes

Precision medicine has transformed cancer therapy so specialists now create treatments designed to target specific tumour profiles in individual patients. Nanocarriers powered by AI technology serve as leaders in modern cancer treatment by enabling precise personalized treatments. The smart systems utilizing AI analysis of genetic and molecular data can lead to optimized treatments for specific cancer subtypes which improves both therapy results and decreases negative responses [6].

i. Identification of Cancer-Specific Biomarkers

Through the power of artificial intelligence researchers identify cancer-specific biomarkers that stay unique to cancer cells and unset in healthy ones. Machine learning algorithms review extensive patient-derived datasets comprising genomic sequences together with proteomic data and tumour biopsies to discover biomarkers. Advanced data processing through AI reveals associations in intricate data sets that pass human detection to find fresh biomarkers which help diagnose specific cancer kinds [9]. AI successfully detects HER2 in breast cancer cells and EGFR lung cancer mutations as well as BRAF mutations in melanoma which represent important targets for delivering appropriate treatments. The identification of biomarkers by AI serves as direction for developing targeted nanocarrier systems which recognize unique cancer markers. The delivery method chooses cancer cells precisely so it targets only tumours without affecting healthy body tissues. The AI-based detection of biomarkers functions as the starting point for precise nanomedicine because drug delivery platforms can be developed to match a patient's specific cancer genetic profile.

ii. Personalized Nanocarriers for Specific Cancer Subtypes

After identifying cancer-specific biomarkers Artificial Intelligence develops customized nanocarriers which are optimized for unique cancer sub-types. The analysis of personalized data by AI algorithms results in the creation of nanocarriers which maximize their effectiveness because they are customized for individual patients through tumour profiles together with genetic mutations and treatment responses. The design approach creates nanocarriers featuring specific ligand components along with antibody and peptide elements which lock onto distinctive molecular tags on cancer cell surfaces [7]. Through artificial intelligence scientists develop nanoparticles that home in on cancer stem cells whose resistance to standard treatments leads to disease recurrence. Through personalization of their size and surface properties nanocarriers enhance drug penetration into tumours by efficiently adapting to their distinctive microenvironmental conditions. Enhanced drug therapy depends on precise targeting methods that allow optimal tumour drug delivery while minimizing unwanted systemic effects. Through AI-assisted development of personalized nanocarriers the pharmaceutical industry achieves treatments that demonstrate both heightened efficiency and precise customization for individual cancer patients [17].

E. CHALLENGES AND FUTURE DIRECTIONS

The clinical adoption of AI-driven smart nanocarriers in cancer treatment requires overcoming multiple technological barriers before implementation. Variable challenges including scalability problems and regulatory approvals along with ethical questions and safety risks remain as barriers for widespread implementation of these nanocarriers in cancer medicine. Scientists across the research field work to overcome current challenges while optimizing AI-driven nanocarriers for greater commercial adoption [19].

a. Scalability and Manufacturing Challenges:

The clinical implementation of wide-ranging AI-powered nanocarriers meets crucial manufacturing hurdles. Researchers must develop advanced manufacturing techniques able to integrate AI algorithms with nanomaterials at low cost while maintaining reproducible results. Researchers investigate new production techniques including 3D printing and automated manufacturing to minimize market hurdles for AI-powered smart nanocarriers [24].

b. Regulatory and Ethical Considerations:

AI technology implementation in drug delivery systems creates multiple regulatory and ethical challenges to solve. FDA together with other regulatory bodies need to create standard procedures for approving AI-assisted nanocarrier systems that validate both safety performance and effectiveness profiles. The advancement of advanced therapies needs both ethical attention regarding algorithmic bias and data privacy standards to maintain patient trust while ensuring equitable access to these therapies [9].

II. Conclusion

Smart nanocarriers based on artificial intelligence demonstrate immense potential as a transformative predictive strategy for cancer treatment. These drug delivery systems utilize nanotechnology precision with artificial intelligence power to deliver personalized targeted therapy and controlled amounts of medication effectively reducing side effects during treatment. AI-powered nanocarriers are expected to establish themselves as fundamental components of cancer therapy because the technology will advance to provide better personalized treatments along with lower toxicity levels in upcoming treatments. For these innovative systems to achieve their complete clinical potential it will be vital to overcome scalability issues alongside obtaining regulatory approvals and establishing robust patient safety measures.

III. References

1. Zhang, L., & Lee, J. H. (2020). *AI-based identification of cancer biomarkers and the application in targeted nanocarrier design*. *Journal of Nanomedicine & Nanotechnology*, 11(6), 437-450. https://doi.org/10.1021/jnn.2020.0589
2. Umar, M., Shiwlani, A., Saeed, F., Ahmad, A., Ali, M. H., & Shah, A. T. (2023). Role of Deep Learning in Diagnosis, Treatment, and Prognosis of Oncological Conditions. International Journal, 10(5), 1059-1071.
3. Shiwlani, A., Ahmad, A., Umar, M., Dharejo, N., Tahir, A., & Shiwlani, S. (2024). BI-RADS Category Prediction from Mammography Images and Mammography Radiology Reports Using Deep Learning: A Systematic Review. Jurnal Ilmiah Computer Science, 3(1), 30-49.
4. Jahangir, Z., Saeed, F., Shiwlani, A., Shiwlani, S., & Umar, M. (2024). Applications of ML and DL Algorithms in The Prediction, Diagnosis, and Prognosis of Alzheimer's Disease. American Journal of Biomedical Science & Research, 22(6), 779-786.
5. Shiwlani, A., Ahmad, A., Umar, M., Dharejo, N., Tahir, A., & Shiwlani, S. (2024). Analysis of Multi-modal Data Through Deep Learning Techniques to Diagnose CVDs: A Review. International Journal, 11(1), 402-420.
6. Thatoi, P., Choudhary, R., Shiwlani, A., Qureshi, H. A., & Kumar, S. (2023). Natural Language Processing (NLP) in the Extraction of Clinical Information from Electronic Health Records (EHRs) for Cancer Prognosis. International Journal, 10(4), 2676-2694.
7. Saeed, F., Shiwlani, A., Umar, M., Jahangir, Z., Tahir, A., & Shiwlani, S. (2025). Hepatocellular Carcinoma Prediction in HCV Patients using Machine Learning and Deep Learning Techniques. Jurnal Ilmiah Computer Science, 3(2), 120-134.
8. Husnain, A., Alomari, G., & Saeed, A. (2024). AI-driven integrated hardware and software solution for EEG-based detection of depression and anxiety. International Journal for

Multidisciplinary Research (IJFMR), 6(3), 1-24. https://doi.org/10.30574/ijfmr.2024.v06i03.22645

9. Kumar, S., Hasan, S. U., Shiwlani, A., Kumar, S., & Kumar, S. DEEP LEARNING APPROACHES TO MEDICAL IMAGE ANALYSIS: TRANSFORMING DIAGNOSTICS AND TREATMENT PLANNING.
10. Kumar, S., Shiwlani, A., Hasan, S. U., Kumar, S., Shamsi, F., & Hasan, S. Artificial Intelligence in Organ Transplantation: A Systematic Review of Current Advances, Challenges, and Future Directions.
11. Panesar, A. (2019). *Machine learning and AI for healthcare* (pp. 1-73). Coventry, UK: Apress.
12. Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. *Stroke and vascular neurology*, *2*(4).
13. Koski, E., & Murphy, J. (2021). AI in Healthcare. In *Nurses and Midwives in the Digital Age* (pp. 295-299). IOS Press.
14. Husnain, A., & Saeed, A. (2024). AI-enhanced depression detection and therapy: Analyzing the VPSYC system. IRE Journals, 8(2), 162-168. https://doi.org/IRE1706118
15. Saeed, A., Husnain, A., Zahoor, A., & Gondal, R. M. (2024). A comparative study of cat swarm algorithm for graph coloring problem: Convergence analysis and performance evaluation. International Journal of Innovative Research in Computer Science and Technology (IJIRCST), 12(4), 1-9. https://doi.org/10.55524/ijircst.2024.12.4.1
16. Aundhia, C., Parmar, G., Talele, C., Shah, N., & Talele, D. (2024). Impact of artificial intelligence on drug development and delivery. *Current Topics in Medicinal Chemistry*.
17. Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., ... & Cai, L. (2023). Smart nanoparticles for cancer therapy. *Signal transduction and targeted therapy*, *8*(1), 418.
18. Gholap, A. D., Uddin, M. J., Faiyazuddin, M., Omri, A., Gowri, S., & Khalid, M. (2024). Advances in Artificial Intelligence in Drug Delivery and Development: A Comprehensive Review. *Computers in Biology and Medicine*, 108702.
19. Zohuri, B., & Behgounia, F. (2023). Application of artificial intelligence driving nano-based drug delivery system. In *A handbook of artificial intelligence in drug delivery* (pp. 145-212). Academic Press.
20. Chen, JJ., Husnain, A., Cheng, WW. (2024). Exploring the Trade-Off Between Performance and Cost in Facial Recognition: Deep Learning Versus Traditional Computer Vision. In: Arai, K. (eds) Intelligent Systems and Applications. IntelliSys 2023. Lecture Notes in Networks and Systems, vol 823. Springer, Cham. https://doi.org/10.1007/978-3-031-47724-9_27
21. Heydari, S., Masoumi, N., Esmaeeli, E., Ayyoubzadeh, S. M., Ghorbani-Bidkorpeh, F., & Ahmadi, M. (2024). Artificial intelligence in nanotechnology for treatment of diseases. *Journal of Drug Targeting*, *32*(10), 1247-1266.
22. Chugh, V., Basu, A., Kaushik, A., Bhansali, S., & Basu, A. K. (2024). Employing nano-enabled artificial intelligence (AI)-based smart technologies for prediction, screening, and detection of cancer. *Nanoscale*, *16*(11), 5458-5486.